Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma
The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.
- The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.
- There were no serious AEs reported in the study, nor any AEs resulting in study drug interruption, withdrawal or discontinuation.
- This suggests that FT011 may have a positive effect for scleroderma patients by reducing the inflammation and fibrosis associated with the disease.
- It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.